Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1

1. Date of Event: June 16, 2026 2. Company Name: Tai康 Biotech Co., Ltd. 3. Relationship to Company: Company itself 4. Cross-shareholding Ratio: Not applicable

5. Reason for Announcement: (1) The Central Bureau of National Health Insurance, Ministry of Health and Welfare, announced today that starting July 1, 2026, the national health insurance coverage for EIRGASUN 420mg will be further expanded for the treatment of HER2-positive early breast cancer (EBC), aligning more closely with international treatment guidelines. The drug was already included in the National Health Insurance reimbursement list starting June 1, 2026. (2) This expansion of insurance coverage is expected to improve clinical accessibility and have a positive impact on the company's operations. (3) According to the Medical Technology Assessment Report by the Foundation of Medical Affairs Evaluation Center, approximately 1,566 to 1,755 early breast cancer patients per year are expected to benefit from this drug over the next five years.

6. Response Measures: Release of material information. 7. Other Matters to be Disclosed: None

Keywords: Material Information